Effect of ezetimibe on the prevalence of cholelithiasis

Advanced Search

BPG is committed to discovery and dissemination of knowledge

Home / Archive / Volume 18, Issue 40

This Article

Citation of this article

Corresponding Author of This Article

Article-Type of This Article

Open-Access Policy of This Article

Times Cited Counts in Google of This Article

Number of Hits and Downloads for This Article

All Articles published online

Item

Count

PDF

290

HTML

2419

Tables (1-1)

196

Sum=2905

Oct 28, 2012 (publication date) through Nov 9, 2024

Times Cited of This Article

Journal Information of This Article

Publication Name

World Journal of Gastroenterology

ISSN

1007-9327

Publisher of This Article

Baishideng Publishing Group Inc, 7041 Koll Center Parkway, Suite 160, Pleasanton, CA 94566, USA

Brief Article

World J Gastroenterol. Oct 28, 2012; 18(40): 5789-5792
Published online Oct 28, 2012. doi: 10.3748/wjg.v18.i40.5789

Table 1 Demographic and clinical characteristics of the patient groups

Study parameters	Study group (statins + ezetimibe) (n = 25)	Control group (statins only) (n =168)	P value
Male/female	13 (52)/12 (48)	76 (46)/92 (55)	0.544
Mean age (yr)	68 ± 8	71 ± 8	0.153
Co-morbidities
Diabetes	11 (44)	57 (34)	0.347
Hypothyroidism	2 (20)	23 (14)	0.449
Ezetimibe treatment
Mean period (d)	799 ± 379
Range (d)	183-1540
Patients with gallstones	4 (16)	33 (20)	0.666

Data are presented as mean ± SD or n (%).

Citation: Stein A, Hermoni D, Elis A, Konikoff FM. Effect of ezetimibe on the prevalence of cholelithiasis. World J Gastroenterol 2012; 18(40): 5789-5792
URL: https://www.wjgnet.com/1007-9327/full/v18/i40/5789.htm
DOI: https://dx.doi.org/10.3748/wjg.v18.i40.5789